federal trade commission

On Thursday, December 17th, the Federal Trade Commission (FTC) announced that it was taking action against six companies selling CBD-based products.  These companies faced administrative actions by the FTC for “making a wide range of scientifically unsupported claims about their ability to treat serious health conditions,” such as cancer, Alzheimer’s disease, and pain relief.  The six actions have been resolved
Continue Reading Operation CBDeceit Marks Beginning of FTC Crackdown on Deceptive CBD Medical Claims While FDA Continues to Issue Warning Letters

On September 10, 2019, the Federal Trade Commission (FTC) sent warning letters to three companies that sold cannabidiol (CBD) products marketed with misleading claims that they could treat serious diseases. The FTC aims to “protect consumers from unfair and deceptive practices in the marketplace,” and accordingly has the responsibility of jointly overseeing marketing and advertising of products that fall under the U.S. Food & Drug Administration’s control.  (In 2019, the FDA issued four warning letters, and publicly disclosed the names of the companies in question. We previously discussed these letters in an earlier article.) According to its press release, the FTC warned three companies that it is illegal to market cures or preventative features of a product without supporting “competent and reliable scientific evidence.” The FTC has not publicly identified the recipients of the letters.
Continue Reading FTC Issues Additional Three Warning Letters to CBD Companies

Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana.

Sadly, the big news this week is vaping.  Hundreds are sick and several have died, apparently as a result of using e-cigarettes and other vaping products.  As a result, the cannabis industry expects fallout from this situation, as states are issuing
Continue Reading The Week in Weed: September 13, 2019